Repligen Corporation Reports Second Quarter 2025 Financial Results

Repligen Corporation, a life sciences company specializing in bioprocessing technology, has released its financial results for the second quarter of 2025. The report highlights significant growth in revenue and orders, alongside updates to the company's financial guidance for the full year.

Financial Highlights

For the second quarter of 2025, Repligen reported a revenue of $182 million, marking a 15% increase year-over-year. The company's GAAP gross profit rose to $91 million from $82 million in the previous year, while adjusted gross profit increased to $93 million from $81 million. GAAP income from operations was $14 million, up from $5 million, and adjusted income from operations was $22 million, compared to $20 million. GAAP net income was $15 million, compared to $6 million, and adjusted net income was $21 million, slightly down from $22 million. GAAP earnings per share (EPS) on a fully diluted basis were $0.26, compared to $0.10, while adjusted EPS was $0.37, down from $0.40.

Business and Operational Highlights

Repligen experienced broad-based revenue strength across all franchises, with consumables up by more than 20% and capital equipment growing in the high-teens. The company also launched ProConnex® MixOne, a single-use mixer based on Metenova’s mixing technology. Additionally, Repligen published its 2024 Sustainability report, "Perspectives on Progress," highlighting progress in various environmental, social, and governance (ESG) initiatives.

Strategic Initiatives and Corporate Developments

The company has raised its revenue guidance for the full year 2025 to a range of $715 to $735 million, representing a 12.5% to 15.5% year-over-year non-COVID organic growth. This update reflects a 1% tailwind from foreign currency, offsetting a 1% headwind from new modalities. The guidance also incorporates a modest impact from tariff surcharges.

Management's Perspective

Olivier Loeillot, President and CEO of Repligen, commented, "We had another outstanding quarter in Q2 with 17% organic non-COVID growth. We are very pleased with the momentum we see across the portfolio. This included strength in both consumables and capital equipment, while biopharma demand continues to perform very well. Orders grew over 20%, which represented the eighth quarter in a row of orders exceeding non-COVID revenue and the fifth quarter of sequential order growth. We believe this is a testament to our differentiated strategy, which resulted in 15% organic non-COVID growth in the first half of 2025."

Future Outlook

Repligen's updated financial guidance for 2025 includes expectations for total reported revenue between $715 million and $735 million, with an adjusted EBITDA margin of 19.5% to 20.5%. The company anticipates a gross margin of 52% to 53% and an adjusted operating margin of 13.5% to 14.5%. The guidance also reflects a tax rate on pre-tax income of 22% to 23% and adjusted net income between $93.5 million and $97 million.

SEC Filing: REPLIGEN CORP [ RGEN ] - 8-K - Jul. 29, 2025